Last reviewed · How we verify
Ondansetron with1:1 ORA - sweet.
At a glance
| Generic name | Ondansetron with1:1 ORA - sweet. |
|---|---|
| Also known as | Zofran |
| Sponsor | Hamad Medical Corporation |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Flavored Intravenous Ondansetron Administered Orally for the Treatment of Persistent Vomiting (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ondansetron with1:1 ORA - sweet. CI brief — competitive landscape report
- Ondansetron with1:1 ORA - sweet. updates RSS · CI watch RSS
- Hamad Medical Corporation portfolio CI